Identifying rare genetic mutations linked to addiction
Deep Sequencing, Phenotyping, and Imputation in Large-Scale Biobanks: A Novel and Cost-Effective Framework to Identify Rare Mutations Associated with Addiction
This study is looking at how our genes might play a role in drug and alcohol addiction, and it's for anyone interested in understanding more about the genetic factors behind these challenges, with the hope of finding new ways to help people struggling with addiction.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10581692 on NIH RePORTER |
What this research studies
This research investigates the genetic factors contributing to drug and alcohol addiction by analyzing large biobanks and identifying rare mutations associated with these behaviors. It employs advanced genomic technologies and a multidisciplinary approach to assess the genetic makeup of individuals and their families. By re-evaluating participants and their relatives, the study aims to gather detailed information on psychiatric traits that are often underrepresented in existing datasets. The ultimate goal is to uncover new genetic targets for potential interventions and treatments for addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of addiction or those who have experienced substance use disorders themselves.
Not a fit: Patients who do not have a history of substance use or addiction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights and treatments for individuals struggling with addiction based on their genetic profiles.
How similar studies have performed: Previous research has successfully identified genetic variants associated with addiction, suggesting that this approach has the potential for significant findings.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Vrieze, Scott Ian — University of Minnesota
- Study coordinator: Vrieze, Scott Ian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.